# Effect of sildenafil citrate on nitric oxide serum levels in patients with unexplained recurrent miscarriages: a randomized clinical trial

#### Chesis

Submitted for partial fulfillment of M.Sc. degree in **Obstetrics and Gynecology** 

# **By Nancy Ahmed Saleh Farahat**

M.B., B.CH (2008) Resident at Air Force Hospital

## Under supervision of

## Ass. Prof. Ahmed Abdel Kader Fahmy

Assistant Professor of Obstetrics and Gynecology Faculty of Medicine Ain Shams University

#### Dr. Tamer Ahmed El-Refaie

Lecturer in Obstetrics and Gynecology Faculty of Medicine Ain Shams University

#### Dr. Manal Mohsen Kamal El-Din

Lecturer in Clinical and Chemical Pathology Faculty of Medicine Ain Shams University

Faculty of Medicine
Ain Shams University
2012



سورة البقرة الآية: ٣٢



To Allah goes My deepest gratitude and thanks for achieving any work in my life.

I would like to express my deepest gratitude to **Dr. Ahmed Abdel Kader Fahmy,** Assistant Professor of Obstetrics and Gynecology, Ain Shams University for dedicating so much of his precious time and effort to help me complete this work. I really appreciate so much his constant guidance and assistance to me.

Indeed, words do fail me when I come to express my unlimited appreciation to **Dr. Tamer Ahmed El-Refaie**, Lecturer of Obstetrics and Gynecology, Ain Shams University who was always there to help me, to encourage me and very kindly offer me his valuable remarks in every step of this work.

I am deeply indebted to **Dr. Manal Mohsen Kamal El-Din**, Lecturer in Clinical and Chemical Pathology, Ain Shams University for her guidance, patience and unlimited assistance and valuable scientific supervision throughout this work.

Finally, I am most grateful to all members of my family for giving me great support.

🖎 Nancy Ahmed



# Contents

Subjects	Page
• List of Abbreviations	I
• List of Tables	IV
• List of Figures	VIII
• Introduction	1
Aim of the Work	3
• Review of literature	
- Unexplained recurrent miscarriage	4
- Sildenafil citrate	60
- Nitric oxide	81
- Placebo	94
Subjects and Methods	98
• Results	125
• Discussion	147
Summary & Conclusions	158
Recommendations	163
• References	
Arabic Summary	

# List of Abbreviations

**ACL** : Anticardiolipin antibodies

**APAS** : Antiphospholipid antibody syndrome

**APS** : Antiphospholipid syndrome

**ARDS** : Adult respiratory distress syndrome

**AUC** : Area under the curve

**BV** : Bacterial vaginosis

**CAT** : Catalase

**cGMP** : Cyclic guanosine monophosphate

**CMV** : Cytomegalovirus

**D&C** : Dilatation and curettage

**DNA** : Deoxyribonucleic acid

**ED** : Erectile dysfunction

**EDRF** : Endothelium-derived relaxing factor

**eNOS** : Endo thelial nitric oxide synthase

**EU** : European union

**FDA** : Federal drug administration

**FIEI** : Female intervention efficacy index

**FSAD**: Female sexual arousal disorder

**FSAD**: Female sexual arousal disorder

**FSFI**: Female sexual function index

**FSH** : Folicule stimulating hormone

**GP** : Glycoprotein

**GSH-S-T** : Glutathione S-transferase

#### E List of Abbreviations

**HCG**: Human chorionic gonadotropin

**HIV** : Human immunodeficiency virus

**HLA**: Histocompatibility leukocyte antigen

**HSDD** : Hypoactive sexual desire disorder

**HSG**: Hysterosalpingogram

**IFN-**γ : Interferon-gamma

Ig : Immunoglobulin

IL : Interleukin

**INR** : International normalized ratio

**ISMO**: Isosorbide mononitrate

**IUFD** : Intrauterine fetal demise

**IUGR** : Intrauterine growth restriction

**IVF** : In vitro fertilization

**IVIg** : Intravenous immunoglobulins

**LAs** : Lupus anticoagulants

**LH** : Luteinizing hormone

**LMWH** : Low-molecular-weight heparin

**LPD** : Luteal phase deficiency

**MDA** : Malondialdehyde

**MRHD**: Maximum recommended human dose

**MRI** : Magnetic resonance imaging

**MTD** : Maximum tolerated dose

**MTHFR** : Methylene tetrahydrofolate reductase

**NADH**: Nicotinamide adenine dinucleotide

#### Tist of Abbreviations

**NAION**: Non-arteritic anterior ischemic optic

neuropathy

NANC : Non-adrenergic, non-cholinergic

**NK** : Natural killer

NO : Nitric oxide

**NO-cGMP**: Nitric oxide-cyclic guanosine monophosphate

pathway

**OD** : Opticaldensity

**PCOS** : Polycystic ovary syndrome

PDE5 : Phosphodiesterase type 5

**PGD**: Preimplantation genetic diagnosis

**PIH** : Pregnancy-induced hypertension

**PT** : Prothrombin time

**RCOG**: Royal college of obstetricians and

gynecologists

**RPL**: Recurrent pregnancy loss

**SD** : Standard deviation

**SLE** : Systemic lupus erythematosis

**SOD** : Superoxide dismutase

**SSRIs** : Selective serotonin uptake inhibitors

**TAC** : Total antioxidant capacity

**TGF-β**: Transforming growth factor-beta

**TNF**: Tumor necrosis factor

**TSH**: Thyrotropin secreting hormone

**URSA** : Unexplained recurrent spontaneous abortion

**VSS**: Visual sexual stimulation

# List of tables

Table No.	Table of content	Page
Table (1)	Reproductive characteristics associated	8
	with poor pregnancy prognosis and	
	recurrent miscarriage.	
Table (2)	Miscarriage rates stratified by maternal	11
	age at conception.	
Table (3)	Prevalence of clinical manifestations in	23
	82 APS patients.	
Table (4)	Prognosis for a Viable Birth Following.	59
Table (5)	Adverse events reported by ≥ 2% of	65
	patients treated with (sildenafil citrate)	
	and more frequent on drug than placebo	
<b>T</b>	in pts flexible-dose phase ii/iii studies.	100
Table (6)	Showing domain scores and sum or	103
	domain score of female sexual domain	
	factor (FSDF).	
	Tables of results	
Table (1)	Statistical comparison between group I	125
	(Sildenafil Citrate) and group II (Placebo)	
	before administration of drug regarding	
	past history.	
Table (2)	Statistical comparison between group I	126
	(Sildenafil Citrate) and group II (Placebo)	
	before administration of drug regarding	
	our routine laboratory investigations for	
	any patients with unexplained recurrent	
	abortion.	

# 🕏 List of Tables 🗷

Table No.	Table of content	Page
Table (3)	Statistical comparison between group I	127
	(Sildenafil Citrate) and group II (placebo)	
	before administration of drug regarding	
	female Sexual function domains.	
Table (4)	Statistical comparison between group I	128
	(Sildenafil Citrate) and group II (Placebo)	
	after administration of drug regarding	
	female Sexual function domains.	
Table (5)	Statistical comparison between before	130
	and after administration of drug in group	
	I (Sildenafil Citrate) regarding female	
	Sexual function domains.	
Table (6)	Statistical comparison between before	131
	and after administration of drug in group	
	II (placebo) regarding female Sexual	
	function domains.	
Table (7)	Statistical comparison between non	133
	circumcised and circumcised females	
	before drug administration in all cases	
	regarding female Sexual function index	
	(FSFI).	
Table (8)	Statistical comparison between non	134
	circumcised and circumcised females	
	after drug administration in group I	
	(Sildenafil Citrate) regarding female	
	Sexual function index (FSFI).	

# 🕏 List of Tables 🗷

Table No.	Table of content	Page
Table (9)	Statistical comparison between group I	136
	(Sildenafil Citrate) and group II (Placebo)	
	before administration of drug regarding	
	expected Sildenafil Citrate side effects.	
<b>Table</b> (10)	Statistical comparison between group I	137
	(Sildenafil Citrate) and group II (Placebo)	
	after administration of drug regarding	
	expected Sildenafil Citrate side effects.	
<b>Table</b> (11)	Statistical comparison in patients in group	139
	I (Sildenafil Citrate) before and after	
	administration of drug regarding expected	
	Sildenafil Citrate side effects	
<b>Table (12)</b>	Statistical comparison in patients in group	140
	II (Placebo) before and after	
	administration of drug regarding expected	
	Sildenafil Citrate side effects	
<b>Table (13)</b>	Statistical comparison between group I	142
	(Sildenafil Citrate) and group II (Placebo)	
	before administration of drug regarding	
	Nitric oxide.	
<b>Table (14)</b>	Statistical comparison between group I	142
	(Sildenafil Citrate) and group II (Placebo)	
	After administration of drug regarding	
	Nitric oxide.	

# 🕏 List of Tables 🗷

Table No.	Table of content	Page
<b>Table (15)</b>	Statistical comparison in patients in group	144
	I (Sildenafil Citrate) before and after	
	administration of drug regarding Nitric	
	oxide.	
<b>Table (16)</b>	Statistical comparison in patients in group	144
	II (placebo) before and after	
	administration of drug regarding Nitric	
	oxide.	
<b>Table (17)</b>	Correlation between before and after	146
	administration of drug regarding Nitric	
	oxide in two groups.	

# List of figures

Fig. No.	Figures of content	Page
<b>Fig.</b> (1)	Number of conceptions expected to reach	7
	each stage of pregnancy.	
Fig. (2)	Range of adverse pregnancy outcomes	7
	IUGR=intrauterine growth restriction.	
Fig. (3)	Proportion of miscarriages due to fetal	10
	aneuploidy by maternal age.	
Fig. (4)	Pathogenic mechanisms of	19
	antiphospholipids antibodies.	
Fig. (5)	Sildenafil citrate is designated chemically	60
	as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-	
	propyl-1Hpyrazolo[4,3d]pyrimidin-5-yl)-4-	
	ethoxyphenyl]sulfonyl]-4 methylpiperazine	
	citrate and has the following structural	
	formula.	
Fig. (6)	Viagra 25 mg.	62
Fig. (7)	Nitric oxide.	81
Fig. (8)	NO Biosynthesis.	82
Fig. (9)	Preparation.	84
Fig. (10)	All types of NOS produce NO from	91
	arginine with the aid of molecular oxygen	
	and NADPH.	
Fig. (11)	Placebo.	94
Fig. (12)	Placebo.	94
Fig. (13)	Placebo.	95



Fig. No.	Figures of content	Page
Fig. (14)	Consort flow diagram of the study.	102
Fig. (15)	Diagram showing preparation of dilution	121
	series of Nitrite Standard.	
	Figures of results	
Fig. (1)	Statistical comparison between group I	129
	(Sildenafil Citrate) and group II (placebo)	
	before administration of drug regarding	
	female Sexual function domains.	
Fig. (2)	Statistical comparison between group I	129
	(Sildenafil Citrate) and group II (Placebo)	
	after administration of drug regarding	
	female Sexual function domains.	
Fig. (3)	Statistical comparison between before and	132
	after administration of drug in group I	
	(Sildenafil Citrate) regarding female	
	Sexual function domains.	
Fig. (4)	Statistical comparison between before and	132
	after administration of drug in group II	
	(placebo) regarding female Sexual function	
	domains.	
Fig. (5)	Statistical comparison between non	135
	circumcised and circumcised females	
	before drug administration in all cases	
	regarding female Sexual function index	
	(FSFI).	

# 🕏 List of Figures 🗷

Fig. No.	Figures of content	Page
Fig. (6)	Statistical comparison between non	135
	circumcised and circumcised females after	
	drug administration in group I (Sildenafil	
	Citrate) regarding female Sexual function	
	index (FSFI).	
Fig. (7)	Statistical comparison between group I	138
	(Sildenafil Citrate) and group II (Placebo)	
	before administration of drug regarding	
	expected Sildenafil Citrate side effects.	
Fig. (8)	Statistical comparison between group I	138
	(Sildenafil Citrate) and group II (Placebo)	
	after administration of drug regarding	
	expected Sildenafil Citrate side effects.	
Fig. (9)	Statistical comparison in patients in group I	141
	(Sildenafil Citrate) before and after	
	administration of drug regarding expected	
	Sildenafil Citrate side effects.	
Fig. (10)	Statistical comparison in patients in group	141
	II (Placebo) before and after administration	
	of drug regarding expected Sildenafil	
	Citrate side effects	
Fig. (11)	Statistical comparison between group I	143
	(Sildenafil Citrate) and group II (Placebo)	
	before administration of drug regarding	
	Nitric oxide.	




Fig. No.	Figures of content	Page
<b>Fig.</b> (12)	Statistical comparison between group I	143
	(Sildenafil Citrate) and group II (Placebo)	
	after administration of drug regarding	
	Nitric oxide.	
Fig. (13)	Statistical comparison in patients in group I	145
	(Sildenafil Citrate) before and after	
	administration of drug regarding Nitric	
	oxide.	
Fig. (14)	Statistical comparison in patients in group	145
	II (placebo) before and after administration	
	of drug regarding Nitric oxide.	
Fig. (15)	Correlation between before and after	146
	administration of drug regarding nitric	
	oxide in group I.	